Viewing Study NCT03255018

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:58 AM
Ignite Modification Date: 2026-03-30 @ 12:08 PM
Study NCT ID: NCT03255018
Status: COMPLETED
Last Update Posted: 2023-11-28
First Post: 2017-08-18
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Hodgkin Lymphoma View
None Lymphoma View
None Diffuse Large B-Cell Lymphoma View
None Gray-zone Lymphoma View
None Primary Central Nervous System Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Monoclonal Antibody View
None PD-1 Receptor View